Addressing the challenges of bispecific antibody characterization with high-throughput platforms

Bispecific antibodies (bsAbs) have emerged as an attractive class of therapeutic agents with the potential to revolutionize the treatment of various disorders. While the concept of bsAbs has been around for several decades, it has taken time for the technology and understanding of antibody engineering to advance to a point where its practical application has become feasible.

The development of bsAbs demands intricate screening processes to identify candidates with desired binding properties, ensuring they induce specific biological activities. Additionally, achieving optimal tissue tropism and potency requires careful consideration of factors such as antibody size, affinity, and the implementation of innovative characterization strategies.

In this context, this whitepaper explores novel approaches contributing to bsAb characterization, offering real-world examples that highlight their practical applications.

For research use only. Not for use in diagnostic procedures.